# EPA/DHA Omega-3 Fatty Acids - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Physiologically, both EPA and DHA act as critical competitive substrates for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. By outcompeting pro-inflammatory arachidonic acid (an Omega-6) for these enzymes, they drastically downregulate the systemic production of inflammatory eicosanoids (prostaglandins and leukotrienes)17. Crucially, they serve as the direct biological precursors for a highly specialized class of immune-resolving autacoids known as Specialized Pro-resolving Mediators (SPMs)—which include resolvins, protectins, and maresins17. Unlike traditional anti-inflammatory pharmaceutical drugs (like NSAIDs) that merely block the initiation pathways of inflammation, SPMs actively orchestrate the actual resolution phase of the inflammatory response17. They achieve this by directly stimulating macrophage phagocytosis to clear out cellular debris, severely lowering serum triglyceride concentrations in the liver, reducing all-cause cardiovascular mortality risk by upwards of 21 percent, and restoring total tissue homeostasis following acute metabolic, physical, or immune stress17.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **92/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 90/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 92/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Physiologically, both EPA and DHA act as critical competitive substrates for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. By outcompeting pro-inflammatory arachidonic acid (an Omega-6) for these enzymes, they drastically downregulate the systemic production of inflammatory eicosanoids (prostaglandins and leukotrienes)17. Crucially, they serve as the direct biological precursors for a highly specialized class of immune-resolving autacoids known as Specialized Pro-resolving Mediators (SPMs)—which include resolvins, protectins, and maresins17. Unlike traditional anti-inflammatory pharmaceutical drugs (like NSAIDs) that merely block the initiation pathways of inflammation, SPMs actively orchestrate the actual resolution phase of the inflammatory response17. They achieve this by directly stimulating macrophage phagocytosis to clear out cellular debris, severely lowering serum triglyceride concentrations in the liver, reducing all-cause cardiovascular mortality risk by upwards of 21 percent, and restoring total tissue homeostasis following acute metabolic, physical, or immune stress17.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **92/100** [Rank #7 of 133 in Heart] - Effect: 25% relative risk reduction in major adverse cardiovascular events (REDUCE-IT)
    - Mechanism: Stabilizes endothelial cell membranes, blunts coronary plaque vulnerability, lowers circulating triglycerides, and decreases platelet thromboxane A2.
- **Chronic Inflammation Reduction**: **89/100** [Rank #10 of 126 in Inflammation] - Effect: Substantial reduction in circulating hs-CRP and production of E-series resolvins
    - Mechanism: Competitively displaces arachidonic acid in phospholipid bilayers, serving as the obligate precursor for Specialized Pro-Resolving Mediators (Resolvins E1/D1, Protectins).

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 2g EPA / 1g DHA
- **Recommended Timing**: With largest fat meal
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: focus, brain_fog, mood, memory, soreness, heart_health

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Active bleeding disorders, Scheduled surgery within 7 days
- **Safety Profile**: low_risk - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression** [PMID: 21939614]
   - Link: https://pubmed.ncbi.nlm.nih.gov/21939614/
2. **DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial** [PMID: 23515006]
   - Link: https://pubmed.ncbi.nlm.nih.gov/23515006/
3. **Omega-3 Polyunsaturated Fatty Acids in the Optimization of Physical Performance** [PMID: 33477966]
   - Link: https://pubmed.ncbi.nlm.nih.gov/33477966/
4. **Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT Trial)** [PMID: 30415628]
   - Link: https://pubmed.ncbi.nlm.nih.gov/30415628/
5. **Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials** [PMID: 31567003]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31567003/
6. **A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain** [PMID: 17493922]
   - Link: https://pubmed.ncbi.nlm.nih.gov/17493922/
7. **Omega-3 fatty acids and inflammatory processes: from molecules to human trials** [PMID: 29958073]
   - Link: https://pubmed.ncbi.nlm.nih.gov/29958073/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [EPA/DHA Omega-3 Fatty Acids on LongevityReviews](https://longevityreviews.org/modalities/epa_dha_omega3)
- **Last Evidence Calibration**: 2026-07-30
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.